estrogen receptor positive

Related by string. Estrogen receptor positive * Estrogen . estrogens . Estrogens : female hormone estrogen . selective estrogen receptor . estrogen receptor negative . estrogen receptor / receptors . Receptor . Receptors : estrogen receptor ER . coupled receptors GPCRs . taste receptors / Positives . Positive . POSITIVE : Rating Watch Positive . tested positive . HER2 positive breast cancer * *

Related by context. All words. (Click for frequent words.) 76 estrogen receptor negative 72 hormone receptor positive 71 estrogen receptor ER 68 HER2 negative 66 atypical hyperplasia 66 progesterone receptor negative 65 HER2 positive 65 hormone receptor negative 64 HER2 positive tumors 64 estrogen receptor progesterone receptor 64 poorer prognosis 62 atypia 62 endometrial cancers 62 HER2 + 61 lobular carcinoma 61 breast cancers 61 BRCA2 mutations 61 HER2 positive cancers 61 breast carcinoma 61 invasive lobular carcinoma 60 advanced adenomas 60 invasive carcinoma 60 estrogen receptor 60 neoadjuvant chemotherapy 60 lymph node involvement 60 distant metastases 60 pancreatic adenocarcinoma 60 operable breast cancer 60 KRAS mutations 60 ductal breast cancer 60 progesterone receptor PR 60 BRCA deficient 59 micrometastases 59 preoperative chemotherapy 59 differentiated thyroid 59 adjuvant chemotherapy 59 invasive ductal 59 adenocarcinomas 59 tumor histology 59 adjuvant therapy 59 BRCA mutation 59 serous ovarian cancer 59 situ LCIS 59 hormone receptor status 59 adenoma 59 taxane therapy 59 squamous cell 59 ductal carcinoma 59 K ras mutations 59 BRCA1 mutations 59 axillary lymph nodes 59 epithelial ovarian 59 breast tumors 59 pCR 59 Adjuvant chemotherapy 59 HGPIN 58 adenocarcinoma 58 invasive ductal carcinoma 58 hormone therapy estrogen 58 oophorectomy 58 EGFR mutations 58 lobular cancer 58 HER2 receptor 58 histological subtype 58 distant metastasis 58 HER2 positive breast 58 HER2 positive metastatic breast 58 SPINK1 58 BRCA2 carriers 58 premenopausal 58 adjuvant radiotherapy 58 HER2 overexpression 58 atypical ductal hyperplasia 58 HNSCC 58 nonmelanoma skin cancers 58 EGFR mutation positive 58 ErbB2 positive 57 neoadjuvant therapy 57 EGFR mutation 57 BRCA mutations 57 castration resistant prostate cancer 57 BRCA1 mutation carriers 57 PSADT 57 seminoma 57 advanced adenoma 57 PCa 57 BRCA mutation carriers 57 nonmetastatic 57 relapsed ovarian cancer 57 mucinous 57 HER2 amplified 57 epithelial tumors 57 BRCA1 mutation 57 HER2 positivity 57 overexpress HER2 57 ductal cancer 57 anaplastic 57 pancreatic lung 57 axillary nodes 57 BRAF mutation 57 Papillary 57 nonsmall cell lung cancer 57 Her2/neu 56 eribulin 56 postmenopausal hormones 56 ovarian cancers 56 salpingo oophorectomy 56 lymph node metastases 56 recurrent VTE 56 sentinel lymph node biopsy 56 recurrent ovarian cancer 56 metastatic prostate 56 colorectal carcinoma 56 HER-2/neu 56 ASCUS 56 renal cell carcinomas 56 LHRH receptor positive 56 lymphovascular invasion 56 endometrial hyperplasia 56 estrogen receptors 56 hormonal therapy 56 breast cancer subtypes 56 basal cell carcinoma BCC 56 metastatic renal cell carcinoma 56 lobular carcinomas 56 estrogen progesterone 56 recurrent ovarian 56 recurrent NSCLC 56 mammographic density 56 aromatase inhibitors AIs 56 tamoxifen 56 prostate carcinoma 56 contralateral breast 56 locoregional recurrence 56 KRAS wild 56 postmenopausal hormone 56 stage IIIb IV 56 Recurrence Score 56 endometrial carcinoma 56 HER2 56 metastatic HER2 negative 56 ERBB2 56 ABCB1 56 small lymphocytic lymphoma 56 castration resistant 56 invasive breast cancer 55 histologies 55 SLNB 55 BRCA2 mutation 55 androgen independent 55 CIN2 + 55 breast carcinomas 55 tumor subtypes 55 CaP 55 anastrozole 55 HER2 positive breast cancer 55 hormone deprivation 55 histologically confirmed 55 liver metastases 55 AGTR1 55 invasive lobular 55 Adenocarcinoma 55 GnRH agonists 55 fibroadenomas 55 KRAS mutation 55 stage IIIB 55 contralateral breast cancer 55 ovarian endometrial 55 TOP2A 55 castrate resistant 55 metastatic prostate cancer 55 lymph node metastasis 55 BRCA gene mutation 55 prostate cancer CaP 55 fallopian tube carcinoma 55 esophageal adenocarcinoma 55 invasive ductal carcinomas 55 cyclophosphamide methotrexate 55 mutated K ras 55 ovarian carcinoma 55 medullary thyroid cancer 55 neoadjuvant treatment 55 hepatocellular carcinomas 55 undergone hysterectomies 55 endocrine therapy 55 adjuvant radiation 55 breast cancer recurrence 55 TGFBR1 * 6A 55 CC genotype 55 flutamide 55 pT2 55 epithelial ovarian cancer 55 peritoneal carcinomatosis 55 prostate cancers 55 metastatic RCC 55 gemcitabine carboplatin 55 axillary dissection 55 mammographic breast density 55 LHRH agonists 55 GBM tumors 55 sarcomatoid 55 premenopausal women 55 unresectable tumors 55 antiangiogenic therapy 55 EBRT 55 node metastases 55 cetuximab 55 pT3 54 HER2 expression 54 subclinical hyperthyroidism 54 standard chemotherapy regimens 54 relapsed SCLC 54 ER CHOP 54 bladder cancers 54 ductal carcinomas 54 basal cell nevus syndrome 54 Zolinza 54 lymphoproliferative disorders 54 dysplastic nevi 54 abnormal mammogram 54 tibolone 54 mutated KRAS 54 sentinel node biopsy 54 lobular breast cancer 54 acute leukemias 54 endoxifen 54 BRAF V# mutation 54 hormone refractory 54 colorectal liver metastases 54 squamous cell carcinoma SCC 54 GISTs 54 adriamycin 54 locoregional 54 B7 H3 54 p# mutation 54 follicular NHL 54 uterine ovarian 54 testicular cancers 54 faulty BRCA genes 54 recurrent glioblastoma multiforme 54 rheumatoid factor 54 alkylating agents 54 T1c 54 MetS 54 chemoradiotherapy 54 biochemical recurrence 54 seminomas 54 BRCA2 mutation carriers 54 gastrointestinal stromal tumors 54 endometrial cancer 54 HBeAg negative 54 tamoxifen Nolvadex ® 54 lymphocytosis 54 endocrine therapies 54 squamous cell lung cancer 54 colorectal adenoma 54 prior chemotherapy regimens 54 MGUS 54 dutasteride 54 CIN3 54 tamoxifen therapy 54 lumbar spine BMD 54 anthracyclines 54 BRAF V#E mutation 54 PSA velocity 54 elevated CRP 54 osteosarcomas 54 cervical carcinoma 54 sentinel nodes 54 leukaemias 54 medically inoperable 54 prostate pancreatic 54 Uterine cancer 54 androgen deprivation therapy 54 tanned indoors 54 gefitinib Iressa 54 bilateral oophorectomy 54 nodal metastasis 54 trabectedin 54 biochemical relapse 54 molecular subtypes 54 chemoresistant 54 carcinoid tumors 54 TT genotype 54 HER2 amplification 54 testicular germ cell 54 pre menopausal 54 EGFR 54 lobular involution 54 Carcinoid tumors 54 cT3 prostate cancer 54 Adriamycin 54 prostate adenocarcinoma 54 neoadjuvant 54 grade gliomas 53 Metastatic 53 parous women 53 metachronous 53 DCIS 53 prostate ovarian 53 stage IIIA 53 aromatase inhibitors 53 ER alpha 53 leukemia CLL 53 progestins 53 GSTT1 53 Her2 positive 53 faulty BRCA2 gene 53 Response Evaluation Criteria 53 pancreatic neuroendocrine tumors 53 bone metastasis 53 extracapsular extension 53 axillary lymph node dissection 53 squamous histology 53 oral squamous cell 53 pancreatic cancers 53 tumors 53 colorectal carcinomas 53 dasatinib 53 BRAF V#E 53 squamous cell cancers 53 telomere lengths 53 perimenopausal women 53 aromatase inhibitor 53 Postmenopausal Women 53 metastatic cancer 53 pheochromocytomas 53 situ DCIS 53 Her2 53 thromboembolisms 53 MTHFR 53 familial pancreatic cancer 53 undergo prostate biopsy 53 raloxifene Evista 53 histologic subtype 53 clinically localized prostate 53 mycosis fungoides 53 axillary node dissection 53 mutated BRCA1 53 Lenalidomide 53 colorectal polyp 53 HER2/neu 53 FLT3 53 cisplatin chemotherapy 53 taxane chemotherapy 53 lobular 53 malignant cancerous 53 Doxil ® 53 follicular lymphomas 53 premalignant 53 Squamous 53 preventive mastectomy 53 skeletal metastases 53 KRAS status 53 adenomatous polyps 53 gemcitabine Gemzar 53 poly ADP ribose polymerase 53 cervical intraepithelial neoplasia 53 anthracycline taxane 53 radiosensitive 53 benign breast 53 curative resection 53 chlamydial infection 53 endometriosis ovarian cysts 53 K ras mutation 53 androgen deprivation 53 prostate cancer PCa 53 Hurthle cell 53 chemoradiation 53 DFMO 53 nonmelanoma 53 myelofibrosis polycythemia vera 53 brain metastases 53 polyp recurrence 53 KRAS mutations occur 53 gastric adenocarcinoma 53 androgen deficiency 53 BRAF mutations 53 urine cytology 53 preoperative PSA 53 resectable 53 cervical lesions 53 prostate tumor 53 HNPCC 53 urothelial carcinoma 53 acute myelogenous leukemia AML 53 uterine cancers 53 BRCA2 gene mutation 53 mammary tumors 53 localized prostate cancer 53 glioma tumors 53 Metastatic breast cancer 53 lobules 53 aromatase 53 breast endometrial 53 Erlotinib 53 EGFR mutant 53 Herceptin trastuzumab 53 LY# [003] 53 invasive ductal breast cancer 53 tyrosine kinase inhibitors 53 EGFr 53 hormonally responsive 53 lung adenocarcinoma 53 SUVmax 53 metastatic disease 53 refractory metastatic 53 SLN biopsy 52 renal tumors 52 nonfasting triglyceride levels 52 olaparib 52 metastatic breast cancer 52 prognostic indicator 52 advanced medullary thyroid 52 lung cancer NSCLC 52 poor metabolizers 52 anti androgen 52 ovarian breast 52 nonalcoholic steatohepatitis NASH 52 sunitinib malate 52 cyclin E 52 tumor recurrence 52 lymph nodes 52 cisplatin resistant 52 ovarian lung 52 Ovary removal 52 nonseminoma 52 FOLFOX4 52 renal carcinoma 52 Squamous cell 52 CYP#D# genotype 52 ADPKD 52 oligodendrogliomas 52 leiomyomas 52 undergo lumpectomy 52 radical nephrectomy 52 5-FU/LV 52 lumpectomy 52 distal colon cancer 52 ApoE4 52 diagnostic biomarker 52 chlorambucil 52 prophylactic mastectomy 52 HER2 ErbB2 52 GSTP1 52 NSCLC tumors 52 lymph node removal 52 essential thrombocythemia 52 colorectal tumors 52 Venous thromboembolism 52 rs# [002] 52 ovarian pancreatic 52 prognostic factor 52 pertuzumab 52 malignancy 52 lipid abnormalities 52 ALND 52 axillary node 52 lung metastasis 52 Metastatic Breast Cancer 52 PKCi 52 SHBG levels 52 adverse cytogenetics 52 tumors GIST 52 narcolepsy cataplexy 52 carcinoid 52 hormonally sensitive 52 factor receptor 52 bendamustine 52 Temsirolimus 52 anal cancers 52 colorectal cancers 52 penetrance 52 serum PSA 52 mTOR inhibitors 52 androgen suppression 52 cell carcinomas 52 papillary 52 EUS FNA 52 hormone therapy 52 heavily pretreated 52 estrogen progestin therapy 52 p# mutations 52 precancerous condition 52 situ CIS 52 erlotinib Tarceva 52 hip BMD 52 progesterone receptor 52 Hashimoto thyroiditis 52 pegylated liposomal doxorubicin 52 antiestrogen 52 iniparib 52 Cholangiocarcinoma 52 hepatic metastases 52 bortezomib 52 metastatic bladder 52 bowel cancers 52 carcinomas 52 EGFR inhibitors 52 intestinal polyps 52 trastuzumab 52 GnRH agonist 52 seminal vesicle invasion 52 platinum refractory 52 Basal cell 52 postmenopausal hormone therapy 52 papillary renal cell carcinoma 52 radiation chemoradiation 52 metastatic 52 mutated KRAS gene 52 neoadjuvant radiation 52 iniparib BSI 52 vandetanib 52 estrogen therapy 52 thyroglobulin 52 #.#ng/ml 52 liposomal doxorubicin 52 subependymal giant cell 52 Tamoxifen 52 luteinizing hormone releasing 52 gliomas 52 gefitinib 52 panobinostat 52 alkylating agent 52 chemopreventive agent 52 gene polymorphism 52 gastric cancers 52 imatinib resistance 52 squamous cell cancer 52 BRCA1 gene 52 Aromasin 52 armpit lymph nodes 52 mycophenolate mofetil 52 FGFR2 52 ovarian cancer 52 AVODART 52 IGFBP 52 malignant pleural mesothelioma 52 K ras 52 premenopausal breast cancer 52 Raf MEK ERK 52 diffuse gastric 52 stage IIIB IV 52 thyroid nodules 52 gallstone disease 52 metastases 52 colorectal gastric 52 NSCLC 52 Irinotecan 52 hypermethylated 52 squamous cell skin 52 lung pancreatic 52 hepatocellular carcinoma HCC 52 nonmelanoma skin cancer 52 liver metastasis 52 NMIBC 52 nucleoside analogue 52 cystectomy 52 imatinib Gleevec 52 Glioma 52 castrate resistant prostate cancer 52 carcinoma 52 cisplatin 52 TIMP 1 52 chemotherapeutic agent 52 Neoadjuvant 52 intravenous bisphosphonates 52 fibrocystic disease 52 hormonal therapies 51 c MYC 51 HPV# 51 serum prostate 51 elevated triglyceride levels 51 curable cancers 51 Ductal carcinoma 51 Bcl xL 51 EGFR protein 51 elevated hsCRP 51 Trastuzumab 51 leukemia AML 51 breast lesions 51 gestational hypertension 51 ARB telmisartan 51 basal cell cancers 51 LRP6 51 docetaxel chemotherapy 51 XELOX 51 oropharyngeal cancer 51 precancerous cervical lesions 51 VEGF inhibitors 51 resistant hormone refractory 51 nonnucleoside reverse transcriptase inhibitors 51 IDH1 mutation 51 cancerous breast 51 T#I [002] 51 non squamous histology 51 PSA screening 51 EpCAM 51 CVD mortality 51 ovaries removed 51 postmenopausal 51 postmenopausal breast cancer 51 breast conserving 51 GNAQ 51 pleural mesothelioma 51 troponin T 51 Hodgkin lymphoma HL 51 hypogonadal 51 elevated LDL cholesterol 51 gemcitabine chemotherapy 51 IGF1R 51 recurrent metastatic 51 serum calcium levels 51 FDG PET 51 anastrazole 51 colorectal neoplasms 51 PTPN# 51 ductal lobular 51 cerebral microbleeds 51 esophageal squamous cell carcinoma 51 xenograft tumors 51 IGF 1R 51 gastrointestinal cancers 51 lenalidomide Revlimid R 51 Folfox 51 prognostic biomarker 51 PCA3 scores 51 refractory AML 51 Alemtuzumab 51 vertebral fracture 51 hormone estrogen 51 estrogen 51 ixabepilone 51 benign lesions 51 T2DM 51 completely resected 51 Leydig cell 51 Memory Study WHIMS 51 debulking surgery 51 neoplasias 51 serum estradiol 51 trans retinoic acid 51 rectal cancers 51 Testicular cancer 51 BRCA carriers 51 leukemia multiple myeloma 51 adjuvant systemic 51 rs# [004] 51 Acute myeloid leukemia 51 CYP#C# [001] 51 mCRC patients 51 mesotheliomas 51 KRAS mutant tumors 51 metastatic lesions 51 specific antigen PSA 51 bleomycin 51 cabazitaxel 51 cytotoxic therapy 51 ovarian tumors 51 lipid lowering drugs 51 oligodendroglioma 51 neoplasia 51 breast uterine 51 micrometastasis 51 postoperative pathology 51 metastatic ocular 51 MALT lymphoma 51 cTnT 51 clodronate 51 hepatocellular cancer 51 gastric cardia 51 epithelioid 51 metastatic colorectal 51 cancer mCRC 51 invasive ductal cancer 51 prostate colon 51 advanced metastatic prostate 51 KRAS gene 51 imatinib resistant 51 Lp PLA2 51 hematopoietic cancers 51 nonsquamous histology 51 aromatase enzyme 51 undergo radical prostatectomy 51 underwent brachytherapy 51 resistant ovarian cancer 51 undergone hysterectomy 51 lymphoid malignancies 51 Relapsing remitting MS 51 malignant lesions 51 colorectal adenomas 51 standard chemotherapy regimen 51 TACE 51 Metastatic colorectal cancer 51 metastatic lung cancer 51 nonischemic cardiomyopathy 51 IV melanoma 51 supratentorial 51 Acute lymphoblastic leukemia 51 antiandrogens 51 Gleevec resistant 51 breast cancer metastasis 51 orchiectomy 51 underwent prostatectomy 51 PDE#A 51 meningioma 51 Uterine fibroids 51 NOLVADEX 51 mutant KRAS 51 TNF blocker therapy 51 AVASTIN 51 ALCL 51 malignant prostate 51 breast cancer gene mutation 51 cutaneous melanoma 51 heavily pretreated patients 51 MDM2 51 subclinical hypothyroidism 51 specific antigen 51 BRCA2 gene mutations 51 glioblastoma tumors 51 FOLFOX6 51 trastuzumab Herceptin R 51 virologic failure 51 malignant gliomas 51 nondiabetic patients 51 PARP inhibitors 51 ErbB2 51 MAGE A3 51 prednisone prednisolone 51 hepatoma 51 estrogen receptor beta 51 chemo radiotherapy 51 Kaplan Meier analysis 51 receptor tyrosine kinase inhibitor 51 Colon polyps 51 dexamethasone Decadron 51 radiochemotherapy 51 vasomotor symptoms 51 genetic polymorphisms 51 microbleeds 51 letrozole 51 Stage IIIb 51 TAXUS Express Stent 51 advanced unresectable 51 activin 51 prognostically 51 hereditary breast cancer 51 squamous cell histology 51 underarm lymph nodes 51 Prostate specific antigen 51 CDK4 51 thyrotropin levels 51 CYT# potent vascular disrupting 51 DLBCL 51 abnormal mammograms 51 atrophic gastritis 51 glandular tissue 51 lung carcinomas 51 Anaplastic 51 prostatic adenocarcinoma 50 catheter angiography 50 naturally occurring estrogen 50 allogeneic stem cell 50 gastric carcinoma 50 Exemestane 50 TTF Therapy 50 TMEM density 50 metastatic tumors 50 prostate cancer CRPC 50 metastatic gastric 50 FOLFIRI 50 CLA supplementation 50 LRP5 50 invasive cervical cancer 50 capecitabine Xeloda 50 lung cancers 50 malignancies 50 prior nephrectomy 50 femoral neck BMD 50 thyrotoxicosis 50 metastatic pancreatic 50 adjuvant tamoxifen 50 advanced metastatic renal 50 BENICAR HCT 50 Bezielle 50 polycystic ovary syndrome PCOS 50 pediatric malignancies 50 osteopenic 50 hamartomas 50 glioblastoma 50 antisense inhibition 50 aromatase inhibitor therapy 50 pulmonary metastases 50 BCG refractory 50 pelvic malignancies 50 Paraplatin ® 50 estrogen receptor alpha 50 non squamous NSCLC 50 PITX2 50 univariate 50 unresectable 50 bevacizumab 50 Adjuvant therapy 50 Follicular lymphoma 50 HER2 receptors 50 letrozole Femara 50 fluoropyrimidine 50 spontaneous preterm birth 50 follicular lymphoma 50 prostate specific 50 Pertuzumab 50 neuroendocrine carcinoma 50 cystatin C 50 thyrotropin 50 Endometrial cancer 50 non resectable 50 prostates removed 50 basal cell skin 50 fibrate drugs 50 fluorouracil 50 advanced neoplasia 50 WT1 50 histologic subtypes 50 neoplasms 50 cutaneous squamous cell carcinoma 50 estramustine 50 intima media thickness 50 metastatic kidney 50 sorafenib Nexavar ® 50 colon tumors 50 carotid stenosis 50 5 Fluorouracil 50 ABVD 50 histologically 50 commonly mutated genes 50 chronic lymphocytic leukemia CLL 50 breast pancreatic 50 rs# [001] 50 urothelial bladder cancer 50 axillary lymph node 50 seronegative 50 symptomatic fibroids 50 ovarian uterine 50 transferrin saturation 50 5FU 50 SERMs 50 prognostic variables 50 Chronic Lymphocytic Leukemia CLL 50 Fc gamma receptor 50 Malignant Melanoma 50 obese postmenopausal 50 prognostic marker 50 promoter methylation 50 Faslodex 50 squamous 50 periprocedural MI 50 BRCA1 50 plus dacarbazine 50 colorectal cancer 50 AstraZeneca Arimidex 50 epithelial cancers 50 malignant neoplasm 50 Bevacizumab 50 papillary carcinoma 50 adjuvant hormonal therapy 50 imatinib 50 Sezary syndrome 50 total thyroidectomy 50 Anastrozole 50 Cristofanilli 50 plus dexamethasone 50 underwent surgical resection 50 hepatic resection 50 HER2 neu 50 Pemetrexed 50 metastatic melanomas 50 TCF#L# 50 MSH2 50 metastatic neuroendocrine tumors 50 prognostic factors 50 Hepatocellular Carcinoma HCC 50 systemic lupus erythematosus 50 mutated BRAF gene 50 proximal colon 50 APTIVUS r 50 vulvar intraepithelial neoplasia 50 adenomatous 50 gastrointestinal stromal tumor GIST 50 sorafenib Nexavar 50 Taxotere ® 50 exemestane 50 thymosin 50 postmenopausal women 50 K ras gene 50 estrogen hormone therapy 50 carotid plaques 50 fluvastatin 50 androgen receptor AR 50 mammary cancers 50 papillary RCC 50 gynecologic malignancy 50 erlotinib 50 lung adenocarcinomas 50 nonfatal MI 50 SNP rs# [001] 50 sleeve lobectomy 50 endogenous estrogen 50 Hormone therapy 50 astrocytomas 50 fibrocystic changes 50 advanced hepatocellular carcinoma 50 subclinical atherosclerosis 50 PSA prostate 50 sFlt 1 50 subtype 50 oesophageal adenocarcinoma 50 EGFR tyrosine kinase inhibitors 50 NF1 50 clinicopathological 50 metastatic GIST 50 adenomas 50 hormones estrogen 50 interferon alfa 50 metastatic malignant 50 Menopausal hormone therapy 50 deCODE BreastCancer TM 50 advanced HER2 positive 50 unresectable stage 50 gene polymorphisms 50 fludarabine 50 decitabine 50 autoantibody positive 50 mutational status 50 thiazides 50 cediranib 50 Aromatase inhibitors 50 SHPT 50 cytoreduction 50 APOL1 50 RBC folate 50 endometrial biopsy 50 overexpress 50 chemoembolization 50 polycystic ovarian syndrome PCOS 50 pazopanib 50 uterine tumors 50 fallopian tube cancers 50 neoplasm 50 pelvic lymphadenectomy 50 hormone LHRH 50 mRCC 50 endostatin 50 non Hodgkin lymphomas 50 BRCA2 50 ZOLINZA 50 clusterin 50 xenograft models 50 gastrointestinal stromal tumor 50 liposarcoma 50 gene amplification 50 abnormal Pap test 50 undergo mastectomy 50 plasma folate 50 geographic atrophy 50 Chemoradiation 50 Glioblastoma multiforme 50 colon polyps 50 PTEN mutations 50 underwent resection 50 dasatinib Sprycel 50 univariate analysis 50 diabetes mellitus DM 50 endometrial kidney 50 alpha folate receptor 50 Glioblastoma 50 SCCHN 50 ERCC1 50 myeloid leukemia 50 MMSE scores 50 FIRMAGON 50 Accelerated Partial Breast Irradiation 49 lipid lowering therapy 49 doxorubicin 49 pancreatic NET 49 EpCAM expression 49 IL#B 49 hypogonadal men 49 lung metastases 49 Estrogens 49 selective estrogen receptor modulators 49 erlotinib Tarceva ® 49 slow metabolizers 49 grade cervical intraepithelial 49 antiplatelet drugs 49 localized renal 49 genistein 49 folate intake 49 deCODE BreastCancer

Back to home page